TI
SPRO icon

Trexquant Investment’s Spero Therapeutics SPRO Stock Holding History

Trexquant Investment’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,151
Closed -$210K – 1847
2022
Q1 		$210K Buy
+24,151
New +$247K 0.01% 1185
2020
Q4 		– Sell
-17,975
Closed -$201K – 1458
2020
Q3 		$201K Buy
+17,975
New +$213K 0.01% 1080
2020
Q2 		– Sell
-13,806
Closed -$112K – 1462
2020
Q1 		$112K Buy
+13,806
New +$122K 0.01% 1037

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Trexquant Investment's SPRO Position: Q2 2022 in Review

Trexquant Investment sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 24,151 shares — an estimated $210K sold.

Trexquant Investment first reported a position in SPRO in Q1 2020 and held it in 3 quarters. The position peaked at $210K in Q1 2022. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Trexquant Investment reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Trexquant Investment sold 24,151 Spero Therapeutics shares in Q2 2022, an estimated $210K.
  • Trexquant Investment first reported a position in Spero Therapeutics in Q1 2020 and held it in 3 quarters.
  • Trexquant Investment's Spero Therapeutics position peaked at $210K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.